ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

N4P N4 Pharma Plc

0.80
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 0.80 0.80 0.80 50,000 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 0 -1.03M -0.0057 -1.40 1.45M
N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.80p. Over the last year, N4 Pharma shares have traded in a share price range of 0.625p to 2.00p.

N4 Pharma currently has 181,080,349 shares in issue. The market capitalisation of N4 Pharma is £1.45 million. N4 Pharma has a price to earnings ratio (PE ratio) of -1.40.

N4 Pharma Share Discussion Threads

Showing 4126 to 4146 of 8600 messages
Chat Pages: Latest  176  175  174  173  172  171  170  169  168  167  166  165  Older
DateSubjectAuthorDiscuss
22/7/2018
15:58
And the biggest reality is that if Nuvec is successful then it will be valued in multiples of all the other reformulations put together if it becomes the industry standard.
So far Nuvec has exceeded all expectations which is why we have the collaboration with Medimmune who are working with N4 to make Nuvec succeed.

hughwilson
22/7/2018
15:43
The market for Viagra has grown by 60% since viagra went OTC three months ago and this figure is increasing. Such is the goal for N4 and yet here it is suggested that N4 will just ditch their formulation without any reference to the final report whatsoever.
The reality as you put it is that nobody including Nigel knows if it is going to be an easy tweak or not. The reality is that Nigel will wait for the final report. The reality is that if it can be tweaked then it will be. The reality is that N4 has not given up on sildenafil. The reality is that given the huge and increasing market, only an idiot would give up at the first fence without looking at the data.
The reality is that we have Nigel in charge with a wealth of experience having done this all before and yet we have those here who think they know so much better but ONLY with hindsight.

hughwilson
21/7/2018
11:14
>> dplewis

Effort in, effort out. Given long enough and enough money I am pretty sure they could sort out the formulation. However, until we see what the issue was we won't know whether there is any chance of just tweaking the current formulation. I somehow doubt it but you never know.

So at the moment I think it is impossible to know the % chance in the short term.

Nobby

nobbygnome
21/7/2018
09:51
Nobby what would you call a good chance of success for a reformulation, 15-20%? I've put the sildenafil down to about 5% after the negative wording in the RNS.I've got a subscription so not sure if you can watch this vid but it's quite interesting how some startups are de-stigmatising conditions such as ED, PE and baldness. If only N4 could get a drug to market..!https://www.bloomberg.com/news/videos/2018-07-19/the-startup-selling-generic-viagra-and-rogaine-to-millenials-video
dplewis1
21/7/2018
08:46
>> hugh

Sadly I am still a shareholder. However, I am a realist. The best way forward is to move on to other products with a better chance of success.

nobbygnome
20/7/2018
21:44
escapetohome, I think you will find that I call a spade a spade or in your case a de-ramper.
Anyway, enjoy it while you can because the bounce will be on soon enough and all the de-rampers will evaporate faster than the morning mist.

hughwilson
20/7/2018
19:18
Hughwilson, stop the paranoid posts.

Please think before you post.

Filtered.

escapetohome
20/7/2018
19:17
Well done dp lewis ,totally correct.

I dont trust hugh wilson one inch.

Sell.

escapetohome
20/7/2018
14:55
Crikey, what a ridiculous price. OVERSOLD. Definitely time to buy:)))
ch1rp
20/7/2018
14:27
right now the rotten black sheep of my portfolio .. hope fortunes change
Just shows you how much money was invested on Sildenafil rather than Nuvec

onedayrodders
20/7/2018
10:02
I think the lack of anything substantial to talk about regarding N4P has brought about a surfeit of drivel across all platforms. At least the sight of Hugh chastising someone for 'de-ramping' has brought some humour to the occasion.
dplewis1
20/7/2018
09:51
It may be an aggressive response, but people returning 3 days after selling with an 'I told you so' deserve to be snapped at. Grow up.
jpsbax
20/7/2018
09:40
plewis1,
It actually reads " better to sell" which is advise and therefore against regulations.

It is a plain de ramp nonetheless.

hughwilson
20/7/2018
09:34
Hugh, do you actually read things properly before you aggressively respond? I'm pretty sure the post from the 17th reads "I sold out" and then the post from today is meaning "I'm glad I sold out because it has declined further". Also your "stream of 100k buys" is a grand total of 3.. which is about 28 grand, so of very little consequence.
dplewis1
20/7/2018
08:44
Just as i thought , better to sell, after that disappointing rns.

All hinges on nuvec.

I dont want that risk.

escapetohome
20/7/2018
08:41
5p by Christmas.It's a failure.
ken chung
17/7/2018
13:52
What was he prior?
turbotrader2
17/7/2018
13:36
You mean this David Farrier RNS? Yes it's an existing holder increasing (substantially) his stake.
dplewis1
17/7/2018
13:24
Can anyone point me in the right direction? Is this increased
turbotrader2
17/7/2018
13:15
Lol, the people who run this company own the company. The only way this share is going is UP!!!!
ch1rp
17/7/2018
12:04
Im out, that should help.
escapetohome
Chat Pages: Latest  176  175  174  173  172  171  170  169  168  167  166  165  Older